Ravi R Gnana, Kim Hak Sung, Servos Jörg, Zimmermann Herbert, Lee Kyeong, Maddileti Savitri, Boyer José L, Harden T Kendall, Jacobson Kenneth A
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases/NIH, Building 8A, Room B1A-17, Bethesda, MD 20892-0810, USA.
J Med Chem. 2002 May 9;45(10):2090-100. doi: 10.1021/jm010538v.
Preference for the Northern (N) ring conformation of the ribose moiety of nucleotide 5'-triphosphate agonists at P2Y(1), P2Y(2), P2Y(4), and P2Y(11) receptors, but not P2Y(6) receptors, was established using a ring-constrained methanocarba (a 3.1.0-bicyclohexane) ring as a ribose substitute (Kim et al. J. Med. Chem. 2002, 45, 208-218.). We have now combined the ring-constrained (N)-methanocarba modification of adenine nucleotides with other functionalities known to enhance potency at P2 receptors. The potency of the newly synthesized analogues was determined in the stimulation of phospholipase C through activation of turkey erythrocyte P2Y(1) or human P2Y(1) and P2Y(2) receptors stably expressed in astrocytoma cells. An (N)-methanocarba-2-methylthio-ADP analogue displayed an EC(50) at the hP2Y(1) receptor of 0.40 nM and was 55-fold more potent than the corresponding triphosphate and 16-fold more potent than the riboside 5'-diphosphate. 2-Cl-(N)-methanocarba-ATP and its N(6)-Me analogue were also highly selective, full agonists at P2Y(1) receptors. The (N)-methanocarba-2-methylthio and 2-chloromonophosphate analogues were full agonists exhibiting micromolar potency at P2Y(1) receptors, while the corresponding ribosides were inactive. Although beta,gamma-methylene-ATP was inactive at P2Y receptors, beta,gamma-methylene-(N)-methanocarba-ATP was a potent hP2Y(1) receptor agonist with an EC(50) of 160 nM and was selective versus hP2Y(2) and hP2Y(4) receptors. The rates of hydrolysis of Northern (N) and Southern (S) methanocarba analogues of AMP by rat 5'-ectonucleotidase were negligible. The rates of hydrolysis of the corresponding triphosphates by recombinant rat NTPDase1 and 2 were studied. Both isomers were hydrolyzed by NTPDase 1 at about half the rate of ATP hydrolysis. The (N) isomer was hardly hydrolyzed by NTPDase 2, while the (S) isomer was hydrolyzed at one-third of the rate of ATP hydrolysis. This suggests that new, more stable and selective nucleotide agonists may be designed on the basis of the (N)-conformation, which greatly enhanced potency at P2Y(1) receptors.
利用环约束的甲碳环(一种3.1.0 - 双环己烷)作为核糖替代物,确定了核苷酸5'-三磷酸激动剂在P2Y(1)、P2Y(2)、P2Y(4)和P2Y(11)受体而非P2Y(6)受体上对核糖部分的北(N)环构象的偏好(Kim等人,《药物化学杂志》,2002年,45卷,208 - 218页)。我们现在已将腺嘌呤核苷酸的环约束(N)-甲碳环修饰与其他已知可增强P2受体活性的功能相结合。通过激活火鸡红细胞P2Y(1)或稳定表达于星形细胞瘤细胞中的人P2Y(1)和P2Y(2)受体来刺激磷脂酶C,从而确定新合成类似物的活性。一种(N)-甲碳环-2-甲硫基-ADP类似物在人P2Y(1)受体上的EC(50)为0.40 nM,比相应的三磷酸酯强55倍,比核糖核苷5'-二磷酸强16倍。2-氯-(N)-甲碳环-ATP及其N(6)-甲基类似物也是P2Y(1)受体上具有高度选择性的完全激动剂。(N)-甲碳环-2-甲硫基和2-氯单磷酸类似物是在P2Y(1)受体上表现出微摩尔活性的完全激动剂,而相应的核糖核苷则无活性。尽管β,γ-亚甲基-ATP在P2Y受体上无活性,但β,γ-亚甲基-(N)-甲碳环-ATP是一种有效的人P2Y(1)受体激动剂,EC(50)为160 nM,对人P2Y(2)和P2Y(4)受体具有选择性。大鼠5'-外切核苷酸酶对AMP的北(N)和南(S)甲碳环类似物的水解速率可忽略不计。研究了重组大鼠NTPDase1和2对相应三磷酸酯的水解速率。两种异构体被NTPDase 1水解的速率约为ATP水解速率的一半。(N)异构体几乎不被NTPDase 2水解,而(S)异构体被水解的速率为ATP水解速率的三分之一。这表明基于(N)-构象可能设计出新型、更稳定且更具选择性的核苷酸激动剂,其在P2Y(1)受体上的活性大大增强。